Patents Assigned to Cetus Corporation
  • Patent number: 5116750
    Abstract: A novel a selectable fusion protein having aminoglycoside phosphotransferase activity is disclosed. The marker comprises the coding sequences for aminoglycoside phosphotransferase I (APH-I) which has been modified and truncated so as to render its use in recombinant vectors more convenient. The modified, truncated sequence (mtAPH-I) gene is capable, upon expression, of conferring resistance to a number of antibiotics on the host. One of these antibiotics, G418, is toxic to eucaryotic as well as procaryotic hosts. Also disclosed are methods of constructing fusion proteins having N-terminal sequences corresponding to a desired peptide sequence, and C-terminal sequences comprising the amino acids encoded by mtAPH-I. The preferred N-terminal sequences are the first 11 amino acids of .beta.-isopropyl malate dehydrogenase, and the first 7 amino acids of yeast enolase.
    Type: Grant
    Filed: July 22, 1988
    Date of Patent: May 26, 1992
    Assignee: Cetus Corporation
    Inventors: David H. Gelfand, Frances C. Lawyer, Susanne Stoffel
  • Patent number: 5116943
    Abstract: A biologically active reference therapeutic protein is protected against oxidation by a method involving substituting a conservative amino acid for each methionyl residue susceptible to chloramine T or peroxide oxidation, wherein additional, non-susceptible methionyl residues are not so substituted. The oxidation-resistant mutein so produced is preferably a human mutein of interleukin-2 or interferon-.beta., and the conservative amino acid is most preferably alanine.
    Type: Grant
    Filed: May 10, 1988
    Date of Patent: May 26, 1992
    Assignee: Cetus Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, David F. Mark, Danutee Nitecti
  • Patent number: 5110920
    Abstract: HLA typing based on restriction length polymorphism is carried out by: digesting an individual's DNA with a restriction endonuclease that produces a polymorphic digestion pattern with HLA DNA; subjecting the digest to genomic blotting using a labeled DNA hybridization probe that hybridizes to an HLA DNA sequence involved in the polymorphism; and comparing the resulting genomic blotting pattern with a standard. This technique may be adapted to make paternity or transplant or transfusion compatibility determinations or to make disease association correlations to diagnose diseases or predict susceptibility to diseases. Locus specific cDNA hybridization probes, particularly probes for genes of Class II loci, for use in the typing procedure are described.
    Type: Grant
    Filed: August 30, 1988
    Date of Patent: May 5, 1992
    Assignee: Cetus Corporation
    Inventor: Henry A. Erlich
  • Patent number: 5104650
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: September 22, 1987
    Date of Patent: April 14, 1992
    Assignee: Cetus Corporation
    Inventors: Peter Ralph, Mary K. Warren, Kong T. Chong, James J. Devlin, Robert Zimmerman, Ada H. C. Kung
  • Patent number: 5104975
    Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.
    Type: Grant
    Filed: July 8, 1988
    Date of Patent: April 14, 1992
    Assignee: Cetus Corporation
    Inventors: Francis P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey
  • Patent number: 5102872
    Abstract: Shipping fever, and other stress-related diseases in livestock, are treated by administration of a microencapsulated composition comprising IL-2 conjugated with a polyoxyethylene polymer, and mixed with a release-modulating amount of humen serum albumin. The microcapsules are administered parenterally, and release an effective amount of conjugated IL-2 continuously over a period of 14-30 days. These microcapsules are also effective in the treatment of cancer in mammals.
    Type: Grant
    Filed: August 12, 1988
    Date of Patent: April 7, 1992
    Assignee: Cetus Corporation
    Inventors: Maninder Singh, Jack H. Nunberg, Thomas R. Tice, Michael E. Hudson, Richard M. Gilley, Terrance A. Taforo
  • Patent number: 5100664
    Abstract: Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
    Type: Grant
    Filed: June 30, 1989
    Date of Patent: March 31, 1992
    Assignee: Cetus Corporation
    Inventors: Michael V. Doyle, Arthur D. Newell, Jack H. Nunberg, Thomas J. White, Gary A. Anderson
  • Patent number: 5098702
    Abstract: Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.
    Type: Grant
    Filed: June 26, 1989
    Date of Patent: March 24, 1992
    Assignee: Cetus Corporation
    Inventors: Robert Zimmerman, Jeffrey L. Winkelhake
  • Patent number: 5098703
    Abstract: A new polypeptide, called IFN-.alpha.76, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.
    Type: Grant
    Filed: September 2, 1982
    Date of Patent: March 24, 1992
    Assignee: Cetus Corporation
    Inventor: Michael A. Innis
  • Patent number: 5096816
    Abstract: This invention relates generally to the field of cell culture. The invention presents pH based methods for controlling the glycosylation patterns of cell products, particularly proteins produced by cells in vitro, preferably via a multi-level pH control strategy. Preferably, this invention is applied to manage the effect of high level of ammonia on the glycosylation of cell products. The glycosylation affected is preferably that of terminal sialylations of the oligosaccharide of glycoproteins.
    Type: Grant
    Filed: June 5, 1990
    Date of Patent: March 17, 1992
    Assignee: Cetus Corporation
    Inventor: Brian L. Maiorella
  • Patent number: 5091310
    Abstract: Structure-independent amplification of DNA by the polymerase chain reaction can be achieved by incorporation of 7-deaza-2'-deoxyguanosine-5'-triphosphate into the amplified DNA.
    Type: Grant
    Filed: September 23, 1988
    Date of Patent: February 25, 1992
    Assignee: Cetus Corporation
    Inventor: Michael A. Innis
  • Patent number: 5089261
    Abstract: The present invention is a process for preparing a pharmaceutical composition comprising a biologically active conjugated protein. It comprises a polyethylene glycol or a polyoxyethylated polyol conjugated to IL-2. This protein is conjugated to reduce its immunogenicity, and increase its solubility, and increase its circulating in vivo half-life.
    Type: Grant
    Filed: September 29, 1989
    Date of Patent: February 18, 1992
    Assignee: Cetus Corporation
    Inventors: Danute E. Nitecki, Nandini Katre, Robert J. Goodson, Lois Aldwin
  • Patent number: 5081010
    Abstract: An extraction composition has been found useful for extracting antigen from herpes simplex virus. This composition has a pH of from about 8.5 to about 12, and comprises an alcoholamine or salt thereof, a nonionic surfactant comprised of a condensation product of an alkylphenol and ethylene oxide, cholic acid or a salt or derivative thereof and an anionic surfactant. Extraction of antigen is accomplished by contacting the extraction composition with a specimen suspected of containing herpes organisms under suitable conditions. Extracted antigen can be determined by forming an immunological complex with antibodies thereto and by detecting that complex. The extraction composition can be supplied as part of a diagnostic test kit.
    Type: Grant
    Filed: February 9, 1989
    Date of Patent: January 14, 1992
    Assignees: Eastman Kodak Company, Cetus Corporation
    Inventors: Thomas J. Cummins, Sheryl S. Sullivan, Randall D. Madsen, Nancy F. Green
  • Patent number: 5078997
    Abstract: The present invention is a pharmaceutical composition for proteins which are not stably soluble. The preferred protein is IL-2 and the preferred composition includes amino acids, vitamins, polymers, fatty acids or low molecular weight acids.
    Type: Grant
    Filed: April 18, 1989
    Date of Patent: January 7, 1992
    Assignee: Cetus Corporation
    Inventors: Maninder S. Hora, Nandini Katre, Kenneth A. Laderman
  • Patent number: 5079351
    Abstract: The presence or absence of a nucleic acid sequence of an isolate of HTLVI and/or HTLVII in a sample containing one or more nucleic acids and suspected of containing such sequence can be detected by amplifying the sequence using primers to form extension products as templates and detecting the amplified product if it is present. This may be accomplished by adding a labeled hydridization probe to the amplified product, either free in solution or after immobilization on a solid support.
    Type: Grant
    Filed: November 26, 1986
    Date of Patent: January 7, 1992
    Assignee: Cetus Corporation
    Inventors: John J. Sninsky, Shirley Y. Kwok, Bernard Poiesz
  • Patent number: 5079163
    Abstract: Ricin B muteins, ricin and ricin precursors having at least one amino acid of at least one galactoside binding site altered to decrease the binding of ricin B to galactosides are claimed. DNA sequences encoding the ricin B muteins, ricin and ricin precursor in which the B chain thereof is the ricin B mutein are claimed. Recombinant expression vectors effective in expressing the DNA sequences of the ricin B muteins, ricin and ricin precursors are claimed. Host cells transformed with the foregoing expression vectors are also claimed. Conjugates comprising binding moieties such as antibodies, hormones, and lymphokines bound to the ricin B mutein and ricin wherein the B chain thereof is the mutein is also claimed.
    Type: Grant
    Filed: March 12, 1987
    Date of Patent: January 7, 1992
    Assignee: Cetus Corporation
    Inventors: Michael Piatak, Jr., L. L. Houston, Anne W. Emerick
  • Patent number: 5079352
    Abstract: Recombinant DNA vectors that encode a thermostable DNA polymerase are useful in the recombinant production of thermostable DNA polymerase. The recombinant thermostable polymerase is preferred for use in the production of DNA in a polymerase chain reaction. Especially useful vectors encode the .about.94,000 dalton thermostable DNA polymerase from thermus aquaticus.
    Type: Grant
    Filed: May 15, 1990
    Date of Patent: January 7, 1992
    Assignee: Cetus Corporation
    Inventors: David H. Gelfand, Susanne Stoffel, Frances C. Lawyer, Randall K. Saiki
  • Patent number: 5075216
    Abstract: Dideoxynucleotide DNA sequencing methods can be dramatically improved by utilizing the DNA polymerase from Thermus aquaticus to catalyze the primer extension reactions.
    Type: Grant
    Filed: September 23, 1988
    Date of Patent: December 24, 1991
    Assignee: Cetus Corporation
    Inventors: Michael A. Innis, Kenneth B. Myambo, David H. Gelfand, Mary Ann D. Brow
  • Patent number: 5066489
    Abstract: Therapeutic treatment of malignant melanoma in humans is disclosed wherein a synergistically effective amount of DTIC in combination with IL-2 is administered to an individual having such cancer.
    Type: Grant
    Filed: July 24, 1990
    Date of Patent: November 19, 1991
    Assignee: Cetus Corporation
    Inventors: Carolyn M. Paradise, Edward C. Bradley
  • Patent number: 5066584
    Abstract: Single stranded DNA can be generated by the polymerase chain reaction using two oligonucleotide primers, one persent in a limiting concentration. The single stranded DNA is useful in procedures involving utilizing nucleic acid probes and for purposes of nucleic acid sequencing.
    Type: Grant
    Filed: September 23, 1988
    Date of Patent: November 19, 1991
    Assignee: Cetus Corporation
    Inventors: Ulf B. Gyllensten, Henry A. Erlich